Biotech CEOs: Can Scientist-Founders Remain In Charge?
A New Breed Of Scientist-Founder: PhD-Carrying Entrepreneurs Who Want To Translate Their Ideas Into Companies
Founder-CEOs do not typically remain at the helm as biotechs mature. Exceptions to that rule are multiplying, though, especially in Europe as companies aim directly for Nasdaq.
You may also be interested in...
Germany is drastically squeezing orphan drug pricing while new US laws protect rare diseases drugs from price negotiations. These contrasting moves fuel the longstanding debate over whether orphans still deserve special incentives.
Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?
Over 100 biopharma companies piled onto public markets in 2021, raising a combined $21bn. A sharp cool off has left many trading well below their listing price. What does it mean for biotech financing in 2022?